These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 18035208)

  • 1. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
    Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N; Davis S; Brazier J
    Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
    Studnička J; Říhová B; Rencová E; Rozsíval P; Dubská Z; Chrapek O; Kolář P; Kandrnal V; Demlová R; Pitrová Š; Řehák J
    Ophthalmologica; 2013; 230(1):34-42. PubMed ID: 23751929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.
    Brown GC; Brown MM; Campanella J; Beauchamp GR
    Am J Ophthalmol; 2005 Oct; 140(4):679-87. PubMed ID: 16226519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
    Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
    Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.
    Wickens J; Blinder KJ
    Drug Saf; 2006; 29(3):189-99. PubMed ID: 16524319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland].
    Donati G
    J Fr Ophtalmol; 2007 Oct; 30(8):837-41. PubMed ID: 17978682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
    Hopley C; Salkeld G; Mitchell P
    Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy.
    Greiner RA
    Semin Ophthalmol; 2001 Dec; 16(4):218-22. PubMed ID: 15513444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.